Highlights

  • Pro Medicus (ASX:PME) reported FY26 customer Revenue of AUD 261.7 million, up 22.9% YoY.
  • Underlying net profit after tax reached AUD 144.7 million, up 24.1% YoY.
  • The company disclosed AUD 252.3 million in cash and other financial Assets at 30 June 2026.
  • Ten new contracts carried a combined minimum value of AUD 407 million during FY26.

Pro Medicus Limited (ASX:PME) develops medical imaging software for hospitals, imaging centres and healthcare organisations, including its Visage 7 platform for viewing and managing clinical images. Pro Medicus shares closed at AUD 193.08 on 2 November 2026. The company’s August FY26 results detailed higher customer revenue, underlying Earnings and contract activity, while identifying product expansion and customer implementations as continuing operational priorities.

How the Medical Imaging Business Operates

Pro Medicus Limited (ASX:PME) supplies radiology information systems, picture archiving and communication systems, advanced image visualisation and related healthcare technology. Its Visage Imaging business supports enterprise imaging workflows, allowing clinicians to review large imaging studies across clinical settings. The company describes deployment Options involving public and private cloud infrastructure. Operations span Australia, North America and Europe, with offices in Melbourne, San Diego and Berlin. Implementations require integration with existing clinical systems.

FY26 Revenue, Earnings and Cash Flow

For the year ended 30 June 2026, Pro Medicus Limited (ASX:PME) reported revenue from contracts with customers of AUD 261.7 million, a 22.9% YoY increase. Underlying earnings before interest and tax were AUD 196.1 million, up 24.4% YoY, with the company reporting an underlying EBIT Margin of 74.9%. Underlying net profit after tax increased 24.1% YoY to AUD 144.7 million. Reported net profit after tax was AUD 265.3 million; the difference from Underlying Profit included fair-value movements associated with financial investments. The measures are not interchangeable.

The company disclosed AUD 252.3 million in cash and other financial assets at 30 June 2026, up 19.7%, and stated it remained debt-free. Its Annual Report recorded net operating cash inflows of AUD 127.5 million. Operating Cash Flow supports spending on product development and delivery.

Contracts and Product Development in 2026

During FY26, Pro Medicus Limited (ASX:PME) signed ten new contracts with a combined minimum value of AUD 407 million and renewed six contracts with a combined value of AUD 141 million. These minimum contract values cover multi-year arrangements rather than revenue recognised immediately. Company disclosures identified contracts with healthcare providers for combinations of image viewing, enterprise imaging and related products.

The August results also described digital pathology and artificial-intelligence-optimised reporting product launches. Management said the Trinity implementation was largely complete, with a full-year contribution anticipated in FY27. A further seven-year, AUD 25 million Valley Health agreement was announced in August 2026. The financial contribution from individual contracts depends on agreed services, implementation stages and recognition of revenue under applicable accounting requirements.

Business-Specific Risks and Operational Priorities

Large healthcare software deployments involve integration with hospital systems, technical testing, Training and clinical workflow changes. Delays could affect the timing of contract-related revenue and implementation costs. Pro Medicus Limited (ASX:PME) also operates across currencies, so exchange-rate movements can influence reported Australian-dollar results. Product reliability, cybersecurity, data governance and healthcare procurement requirements remain relevant operational considerations.

Monitoring points include the progress of signed implementations, uptake of additional software modules, contract renewals, continuing Investment in digital pathology and reporting tools, and the relationship between underlying profit and statutory results. Operating cash conversion also warrants monitoring.

Key Insights

Pro Medicus Limited (ASX:PME) reported FY26 growth in customer revenue and underlying earnings, alongside positive operating cash inflows and a debt-free position. Multi-year contracts and new imaging products provide observable indicators of its activities, although contract values are not equivalent to near-term revenue. Implementation progress, currency exposure, product investment and financial reporting distinctions remain central to assessing subsequent company updates.